- Home
- MIND vs PRLD Comparison
MIND vs PRLD Comparison
Compare MIND & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIND
- PRLD
- Stock Information
- Founded
- MIND 1987
- PRLD 2016
- Country
- MIND United States
- PRLD United States
- Employees
- MIND N/A
- PRLD N/A
- Industry
- MIND Industrial Machinery/Components
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- MIND Industrials
- PRLD Health Care
- Exchange
- MIND Nasdaq
- PRLD Nasdaq
- Market Cap
- MIND 49.6M
- PRLD 44.0M
- IPO Year
- MIND 1994
- PRLD 2020
- Fundamental
- Price
- MIND $10.50
- PRLD $1.01
- Analyst Decision
- MIND
- PRLD Strong Buy
- Analyst Count
- MIND 0
- PRLD 3
- Target Price
- MIND N/A
- PRLD $4.00
- AVG Volume (30 Days)
- MIND 235.3K
- PRLD 133.9K
- Earning Date
- MIND 09-10-2025
- PRLD 08-14-2025
- Dividend Yield
- MIND N/A
- PRLD N/A
- EPS Growth
- MIND N/A
- PRLD N/A
- EPS
- MIND 2.91
- PRLD N/A
- Revenue
- MIND $45,087,000.00
- PRLD $7,000,000.00
- Revenue This Year
- MIND $7.27
- PRLD N/A
- Revenue Next Year
- MIND N/A
- PRLD N/A
- P/E Ratio
- MIND $3.61
- PRLD N/A
- Revenue Growth
- MIND 26.68
- PRLD N/A
- 52 Week Low
- MIND $3.05
- PRLD $0.61
- 52 Week High
- MIND $11.10
- PRLD $5.95
- Technical
- Relative Strength Index (RSI)
- MIND 58.61
- PRLD 52.78
- Support Level
- MIND $9.27
- PRLD $0.75
- Resistance Level
- MIND $10.87
- PRLD $0.96
- Average True Range (ATR)
- MIND 0.64
- PRLD 0.08
- MACD
- MIND -0.02
- PRLD 0.01
- Stochastic Oscillator
- MIND 66.18
- PRLD 67.87
About MIND MIND Technology Inc. (DE)
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.